T. Rowe Price Associates
PVLA

T. Rowe Price Associates’s Palvella Therapeutics PVLA Stock Holding History

T. Rowe Price Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.2M Buy
402,564
+398,474
+9,743% +$41.6M 0.01% 767
2025
Q4 		$429K Buy
4,090
+433
+12% +$36.9K ﹤0.01% 2463
2025
Q3 		$230K Buy
+3,657
New +$163K ﹤0.01% 2737

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

T. Rowe Price Associates's PVLA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Palvella Therapeutics (PVLA) stake by 9,743% in Q1 2026, buying an estimated $41.6M and bringing the position to 402,564 shares worth $50.2M. The position accounts for 0.01% of the portfolio, ranked #767.

T. Rowe Price Associates first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • T. Rowe Price Associates held 402,564 shares of Palvella Therapeutics worth $50.2M as of Q1 2026.
  • T. Rowe Price Associates bought 398,474 Palvella Therapeutics shares in Q1 2026, an estimated $41.6M.
  • Palvella Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #767 holding.
  • T. Rowe Price Associates first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.